Announcement

Collapse
No announcement yet.

ABSTRACT: Immune Responses of Healthy Subjects to a Single Dose of Intramuscular Inactivated Influenza A/Vietnam/1203/2004 (H5N1) Vaccine

Collapse
X
 
  • Filter
  • Time
  • Show
Clear All
new posts

  • ABSTRACT: Immune Responses of Healthy Subjects to a Single Dose of Intramuscular Inactivated Influenza A/Vietnam/1203/2004 (H5N1) Vaccine

    The Journal of Infectious Diseases 2008;198:635?641
    ? 2008 by the Infectious Diseases Society of America. All rights reserved.
    0022-1899/2008/19805-0003$15.00
    DOI: 10.1086/590916


    Immune Responses of Healthy Subjects to a Single Dose of Intramuscular Inactivated Influenza A/Vietnam/1203/2004 (H5N1) Vaccine after Priming with an Antigenic Variant
    Nega Ali Goji,1
    Carrie Nolan,1
    Heather Hill,2
    Mark Wolff,2
    Diana L. Noah,3
    Tracy B. Williams,3
    Thomas Rowe,3 and
    John J. Treanor1
    1University of Rochester Medical Center, Rochester, New York; 2EMMES Corporation, Rockville, Maryland; 3Southern Research Institute, Birmingham, Alabama

    Background.
    We administered a single dose of influenza A/Vietnam/1203/2004 (H5N1, clade 1) vaccine to subjects who had received 2 doses of influenza A/Hong Kong/156/1997 (H5N1, clade 0) vaccine in 1998.

    Methods.
    Thirty-seven subjects previously vaccinated with a baculovirus-expressed recombinant hemagglutinin A/Hong Kong/156/1997 vaccine in 1998 received a single intramuscular dose of 90 μg of inactivated subvirion A/Vietnam/1203/2004 vaccine in 2006. Serum antibody was measured before vaccination and 28 and 56 days after vaccination. Antibody responses were compared with those measured after one or two 90-μg doses in H5-naive subjects.

    Results.
    On day 28 after a single dose, the geometric mean titer (GMT) of hemagglutination-inhibition antibody in primed subjects was 64.0 (95% confidence interval [CI], 37.8?108.5), with 68% responding (4-fold increase in antibody level to a titer of 1:40). In contrast, H5-naive subjects who received two 90-μg doses had a day 56 (28 days after the second dose) GMT of 27.7 (95% CI, 20.3?38.0), with only 43% responding.

    Conclusions.
    This study suggests that priming can result in immune responses to a single dose of an antigenically variant strain of H5N1 influenza virus and could be a useful strategy for pandemic control.

    Trial registration. ClinicalTrials.gov identifier: NCT00240903.

    Received 16 January 2008; accepted 28 April 2008; electronically published 24 June 2008.


    Discussion at: http://www.flutrackers.com/forum/showthread.php?t=74371
Working...
X